Corixa Bexxar ruling reversed
Executive Summary
Biogen Idec motion for summary judgment in Bexxar (tositumomab) patent litigation denied by San Diego federal court Jan. 22, reversing previous order. The court granted Biogen's motion on Oct. 14, 2003, holding that Corixa's Bexxar patents (nos. 5,595,721; 6,015,542; 6,090,365; and 6,287,537) were unenforceable (1"The Pink Sheet" Oct. 20, 2003, In Brief). Litigation in San Diego court will continue...